Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19153405 | 0.88 | NOS3 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL18237677 | 0.78 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL8533330 | 0.71 | NOS3 (0.59) | CYP2A6NOS3NOS1NOS2 | |
| SCHEMBL13021590 | 0.71 | NOS3 (0.53) | CYP2A6NOS3NOS1NOS2 | |
| SCHEMBL14510366 | 0.70 | PDE3B (0.31) | MEN1KMT2A | |
| SCHEMBL18237548 | 0.70 | NOS3 (0.31) | NOS3NOS1NOS2 | |
| SCHEMBL21035410 | 0.69 | NOS3 (0.57) | CYP2A6NOS3NOS1NOS2 | |
| SCHEMBL25771762 | 0.69 | NOS3 (0.57) | CYP2A6NOS3NOS1NOS2 | |
| SCHEMBL25795844 | 0.69 | NOS3 (0.57) | CYP2A6NOS3NOS1NOS2 | |
| SCHEMBL14510379 | 0.69 | PDE3B (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | MEN1 380/4885KMT2A 1005/4885CYP2A6 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.